# Nektar Therapeutics (NKTR) — News

NKTR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/nktr/news

## Recent headlines

- [Nektar Therapeutics - Salt score ≤20 response maintained in 75% at 4 months, 63% at 6 months off treatment](https://www.ainvest.com/news/nektar-therapeutics-salt-score-20-response-maintained-75-4-months-63-6-months-treatment-2610) — AInvest Wire, Oct 1, 2026
- [Nektar Therapeutics - 19% achieve salt score ≤10 at 6 months off treatment, up from 7% at 52 weeks](https://www.ainvest.com/news/nektar-therapeutics-19-achieve-salt-score-10-6-months-treatment-7-52-weeks-2610) — AInvest Wire, Oct 1, 2026
- [Nektar Therapeutics - Phase 3 Zenith AA study to initiate in early 2027](https://www.ainvest.com/news/nektar-therapeutics-phase-3-zenith-aa-study-initiate-early-2027-2610) — AInvest Wire, Oct 1, 2026
- [Nektar Therapeutics - Rezpegaldesleukin demonstrates durability and deepening of response through one year of treatment](https://www.ainvest.com/news/nektar-therapeutics-rezpegaldesleukin-demonstrates-durability-deepening-response-year-treatment-2610) — AInvest Wire, Oct 1, 2026
- [Nektar announces three oral presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026](https://www.ainvest.com/news/nektar-announces-oral-presentations-rezpegaldesleukin-european-academy-dermatology-venereology-eadv-congress-2026-2609) — AInvest Wire, Sep 28, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).